The long-term objective of this research is to develop a clinically translatable strategy to repair soft tissue defects resulting from cancer, trauma, congenital abnormalities, and infections. Repair of soft tissue defects with tissue engineered fat grafts are the ideal solution to obviate many current limitations in reconstructive surgery. However, the fundamental question of how engineered fat grafts survive remains largely unanswered. The immediate objective of this proposal is to address three fundamental issues that hinder the progress of adipose tissue engineering. We hypothesize that successful grafting of engineered fat is linked to the cellular composition of the graft and the microenvironment of the graft's recipient site is tested.
Three specific aims i nvestigate this hypothesis utilizing an integrated, multidisciplinary approach.
Aim 1 focuses on defining the cellular composition of syringe-aspirated human fat as a function of the techniques used to process harvested fat for implantation. Flow cytometry is employed to identify and quantify cell populations.
In Aim 2, we determine the relationship between engineered fat graft volume and local blood supply. This critical design parameter is elucidated using quantitative histomorphometry and a xenograft model that incorporates a fat construct possessing its own pedicled blood supply.
Aim 3 concentrates on determining the requisite role of the recruitment of resident fat precursor and stem cells. The development of an engineered fat graft will broadly impact health care related to soft tissue defects caused by cancer, trauma, congenital abnormalities, and infections. Understanding the cell populations involved in fat grafting and blood supply dependence of fat grafts are critical mechanisms that affect the design of an engineered fat graft. Moreover, the involvement of resident adipogenic cells at the site of fat grafting may modulate the survival of fat grafting. These fundamental issues, once understood, offer the potential to mimic or modulate these activities for novel bioinspired technologies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21EB007587-02
Application #
7574389
Study Section
Bioengineering, Technology and Surgical Sciences Study Section (BTSS)
Program Officer
Hunziker, Rosemarie
Project Start
2008-03-01
Project End
2012-11-30
Budget Start
2010-03-01
Budget End
2012-11-30
Support Year
2
Fiscal Year
2010
Total Cost
$190,575
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Schools of Engineering
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030